Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Shares Outstanding (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Shares Outstanding for 3 consecutive years, with $40.5 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Shares Outstanding rose 101273.53% year-over-year to $40.5 million, compared with a TTM value of $40.5 million through Mar 2024, up 101273.53%, and an annual FY2023 reading of $40.3 million, up 101858.85% over the prior year.
  • Shares Outstanding was $40.5 million for Q1 2024 at Oramed Pharmaceuticals, roughly flat from $40.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $40.5 million in Q1 2024 and bottomed at $38564.0 in Q1 2022.
  • Average Shares Outstanding over 3 years is $10.1 million, with a median of $39767.0 recorded in 2022.
  • Peak annual rise in Shares Outstanding hit 101858.85% in 2023, while the deepest fall reached 95.25% in 2023.
  • Year by year, Shares Outstanding stood at $39564.0 in 2022, then skyrocketed by 101858.85% to $40.3 million in 2023, then increased by 0.45% to $40.5 million in 2024.
  • Business Quant data shows Shares Outstanding for ORMP at $40.5 million in Q1 2024, $40.3 million in Q4 2023, and $40219.0 in Q2 2023.